BBIO - Why BridgeBio Pharma Stock Is Trading Lower Tuesday | Benzinga
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is moving lower Tuesday after the company announced results from its Phase 2 trial of infigratinib in children with achondroplasia.
What Happened: The results showed statistically significant improvement in body proportionality at month 18. In addition, it showed statistically significant increased annualized height velocity at month 12 and 18.
The treatment ...